Public summary of opinion on orphan designation Cisplatin for the treatment of malignant mesothelioma
![EMA Klinec, de Slovénie, vu en action lors de la compétition de saut à ski féminin HS102 aux Championnats du monde de ski nordique FIS 2023. (Photo par Andrej Tarfila / SOPA EMA Klinec, de Slovénie, vu en action lors de la compétition de saut à ski féminin HS102 aux Championnats du monde de ski nordique FIS 2023. (Photo par Andrej Tarfila / SOPA](https://c8.alamy.com/compfr/2nkbx8b/ema-klinec-de-slovenie-vu-en-action-lors-de-la-competition-de-saut-a-ski-feminin-hs102-aux-championnats-du-monde-de-ski-nordique-fis-2023-photo-par-andrej-tarfila-sopa-images-sipa-usa-2nkbx8b.jpg)
EMA Klinec, de Slovénie, vu en action lors de la compétition de saut à ski féminin HS102 aux Championnats du monde de ski nordique FIS 2023. (Photo par Andrej Tarfila / SOPA
![Frontiers | Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021 Frontiers | Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021](https://www.frontiersin.org/files/MyHome%20Article%20Library/920336/920336_Thumb_400.jpg)
Frontiers | Licensing of Orphan Medicinal Products—Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021
![Frontiers | Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe Frontiers | Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe](https://www.frontiersin.org/files/Articles/924648/fphar-13-924648-HTML-r2/image_m/fphar-13-924648-g001.jpg)